Structural harms and COVID-19 policy responses in Manitoba: Exploring the experiences of Red River Métis

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:239 publications

Grant number: Unknown

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2021
  • Known Financial Commitments (USD)

    $394,889.4
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    N/A

  • Research Location

    Canada
  • Lead Research Institution

    University of Manitoba
  • Research Priority Alignment

    N/A
  • Research Category

    Policies for public health, disease control & community resilience

  • Research Subcategory

    Approaches to public health interventions

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Why this research is needed: Systematically marginalized populations, such as First Nations/Metis/Inuit (FN/M/I), have been greatly affected by COVID-19 in Canada. This is why people identifying as FN/M/I were prioritized for COVID-19 vaccines. This policy was adopted Canada-wide, except in Manitoba. In Manitoba, only First Nations Peoples were prioritized for COVID-19 vaccines. Inuit and Metis Citizens were to access COVID-19 vaccines following age-eligibility criteria like all other Manitobans. This policy changed in May 2021 in acknowledgement of the "impacts of colonization on all Indigenous people in Canada". Vaccines were handled differently during H1N1, where only Manitoba prioritized people of Indigenous Ancestry (FN/I/M) for H1N1 vaccine in Canada. Manitoba's COVID-19 vaccine policy has had a negative impact on vaccine uptake by the Red River Metis. In this project we aim to study: 1.Ongoing COVID-19 vaccine decision-making processes among Metis Citizens; 2.Harms (e.g. COVID-19 infection rates, health service use for COVID-19, lower vaccine uptake) created by a racist policy that disadvantaged Metis relative to all other Manitobans; 3.The impact on possible COVID-19 cases if Red River Metis had been prioritized for vaccination earlier in the pandemic; and 4.Long-term consequences and possible loss of trust among Metis in provincial health systems. Methods: We will carry out focus group discussions with Red River Metis (obj 1, 2, 4) to examine Metis experiences given the provincial public health COVID response, and use whole-population administrative health and COVID vaccination data, updated monthly, to compare Metis experiences to all other Manitobans (obj 2, 3). Impact: As we enter the fourth wave, we need to document the experiences of Red River Metis relative to all other Manitobans. Only then might we be able to better understand how we can close the gap in Metis vaccine uptake.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Development and Validation of the Intimate Partner Violence Workplace Disruptions Assessment (IPV-WDA).

Elucidating directed neural dynamics of scene construction across memory and imagination

Implementing a Novel Resident-Led Peer Support Program for Emergency Medicine Resident Physicians.

Cross-Activity Analysis of CRISPR/Cas9 Editing in Gene Families of <i>Solanum lycopersicum</i> Detected by Long-Read Sequencing.

Creating health systems citizens: enhanced professional identity formation through a para-curricular distinction track in health systems transformation and leadership.

A Comparison of Clinical Diagnostic Classification Criteria Used in Longitudinal Cohort Studies of the Alzheimer's Disease Continuum: A Systematic Review.

Identification and Characterization of a Rare Exon 22 Duplication in <i>CFTR</i> in Two Families.

Structural Rearrangement in Cyclic Cu(II) Pyridyltriazole Complexes: Oxidation of Dabco to Oxalate and CO<sub>2</sub> Conversion to Carbonate.

Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use.